Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. Melflufen is an investigational drug and is not approved for commercial use.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen in multiple myeloma. Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
The shareholders in Oncopeptides AB are given notice to attend the EGM to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden, on Tuesday 17 December 2019 at 3.00 p.m. Coffee will be served starting at 2.30 p.m., at which time the registration for attendees will commence.
Oncopeptides held an operational update on Tuesday, November 19, 2019. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team. The webcast was recorded.